Stock Track | Oruka Therapeutics Soars 5.42% in Pre-market on Analyst Target Price Hikes

Stock Track

04/28

Oruka Therapeutics Inc's stock surged 5.42% during pre-market trading on Tuesday, following positive analyst actions that boosted investor sentiment.

The significant price movement comes after Barclays raised its target price for Oruka Therapeutics to $160 from $78, representing a substantial increase in valuation expectations. Additionally, UBS also increased its target price for the company to $100 from $75, further supporting the positive outlook for the healthcare stock.

Analysts have shown increased interest in Oruka Therapeutics, with mixed opinions emerging on healthcare sector stocks including both Zoetis and Oruka Therapeutics. The dual target price upgrades from major financial institutions appear to have driven the pre-market surge as investors react to the improved valuation assessments.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1122386649"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1122386649\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1122386649?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-28 21:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122386649","market":"nz","top_or_hot":-1,"title":"Stock Track | Oruka Therapeutics Soars 5.42% in Pre-market on Analyst Target Price Hikes","media":"Stock Track","content":"<p>Oruka Therapeutics Inc's stock surged 5.42% during pre-market trading on Tuesday, following positive analyst actions that boosted investor sentiment.</p><p>The significant price movement comes after Barclays raised its target price for Oruka Therapeutics to $160 from $78, representing a substantial increase in valuation expectations. Additionally, UBS also increased its target price for the company to $100 from $75, further supporting the positive outlook for the healthcare stock.</p><p>Analysts have shown increased interest in Oruka Therapeutics, with mixed opinions emerging on healthcare sector stocks including both Zoetis and Oruka Therapeutics. The dual target price upgrades from major financial institutions appear to have driven the pre-market surge as investors react to the improved valuation assessments.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Oruka Therapeutics Soars 5.42% in Pre-market on Analyst Target Price Hikes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Oruka Therapeutics Soars 5.42% in Pre-market on Analyst Target Price Hikes\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-04-28 21:12</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Oruka Therapeutics Inc's stock surged 5.42% during pre-market trading on Tuesday, following positive analyst actions that boosted investor sentiment.</p><p>The significant price movement comes after Barclays raised its target price for Oruka Therapeutics to $160 from $78, representing a substantial increase in valuation expectations. Additionally, UBS also increased its target price for the company to $100 from $75, further supporting the positive outlook for the healthcare stock.</p><p>Analysts have shown increased interest in Oruka Therapeutics, with mixed opinions emerging on healthcare sector stocks including both Zoetis and Oruka Therapeutics. The dual target price upgrades from major financial institutions appear to have driven the pre-market surge as investors react to the improved valuation assessments.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ORKA","symbol_name":"ORUKA THERAPEUTICS INC","start_time":0,"source_url":"","article_id":"1122386649","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122386649","pubTimestamp":1777381961,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Oruka Therapeutics Inc's stock surged 5.42% during pre-market trading on Tuesday, following positive analyst actions that boosted investor sentiment.The significant price movement comes after...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ORKA":"ORUKA THERAPEUTICS INC"},"translate_title":"个股追踪|分析师上调目标价Oruka Therapeutics盘前大涨5.42%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ORKA":1},"content_text":"Oruka Therapeutics Inc's stock surged 5.42% during pre-market trading on Tuesday, following positive analyst actions that boosted investor sentiment.The significant price movement comes after Barclays raised its target price for Oruka Therapeutics to $160 from $78, representing a substantial increase in valuation expectations. Additionally, UBS also increased its target price for the company to $100 from $75, further supporting the positive outlook for the healthcare stock.Analysts have shown increased interest in Oruka Therapeutics, with mixed opinions emerging on healthcare sector stocks including both Zoetis and Oruka Therapeutics. The dual target price upgrades from major financial institutions appear to have driven the pre-market surge as investors react to the improved valuation assessments.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}